Integrated Safety Analysis of Ritlecitinib in Adolescent Patients With Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b 3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies. J of Skin 2023, 7 (6), s294. https://doi.org/10.25251/skin.7.supp.294.